Evidence map›Paper›PMID 35946107›Full record

Trial reportMultiple sclerosis (Houndmills, Basingstoke, England)2022

Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial.

Thomas Williams, Carmen Tur, Arman Eshaghi, Anisha Doshi, Dennis Chan, Sophie Binks, Henny Wellington, Amanda Heslegrave, Henrik Zetterberg, Jeremy Chataway

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Multiple sclerosis (Houndmills, Basingstoke, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Exercise Training and Biomarkers of Neuroaxonal Injury in Multiple Sclerosis: Narrative Review.International journal of environmental research and public health · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Cognitive impairment in multiple sclerosis: from phenomenology to neurobiological mechanisms.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Thomas WilliamsQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, Russell Square House, 10-12 Russell Square, London WC1B 5EH, UK.ORCID 0000-0002-8197-0177
Carmen TurQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK/Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron Institute of Research, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Arman EshaghiQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK.
Anisha DoshiQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK.
Dennis ChanUCL Institute of Cognitive Neuroscience, University College London, London, UK.
Sophie BinksDepartment of Neurology, Nuffield Department of Clinical Neurosciences, Oxford, UK.
Henny WellingtonUK Dementia Research Institute, University College London, London, UK.
Amanda HeslegraveUK Dementia Research Institute, University College London, London, UK.
Henrik ZetterbergUK Dementia Research Institute, University College London, London, UK/ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden/Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden/Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK/Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.
Jeremy ChatawayQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK/National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK/Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Queen Mary University of London · GBUK Dementia Research Institute · GBUniversity College London · GBNational Institute for Health Research · GBNuffield Orthopaedic Centre · GBSahlgrenska University Hospital · SE

Funding

Department of Health
6 · The paper itself

Abstract

backgroundCognitive impairment affects 50%-75% of people with secondary progressive multiple sclerosis (PwSPMS). Improving our ability to predict cognitive decline may facilitate earlier intervention.

objectiveThe main aim of this study was to assess the relationship between longitudinal changes in cognition and baseline serum neurofilament light chain (sNfL) in PwSPMS. In a multi-modal analysis, MRI variables were additionally included to determine if sNfL has predictive utility beyond that already established through MRI.

methodsParticipants from the MS-STAT trial underwent a detailed neuropsychological test battery at baseline, 12 and 24 months. Linear mixed models were used to assess the relationships between cognition, sNfL, T2 lesion volume (T2LV) and normalised regional brain volumes.

resultsMedian age and Expanded Disability Status Score (EDSS) were 51 and 6.0. Each doubling of baseline sNfL was associated with a 0.010 [0.003-0.017] point per month faster decline in WASI Full Scale IQ Z-score (

conclusionElevated sNfL is associated with faster cognitive decline, independent of T2LV and regional normalised volumes.

Indexed as

Cognitive DysfunctionMultiple SclerosisMultiple Sclerosis, Chronic ProgressiveBiomarkersHumansIntermediate FilamentsMagnetic Resonance ImagingNeurofilament ProteinsBiomarkersNeurofilament Proteinsbiomarkerscognitionmagnetic resonance imagingMultiple sclerosisneurofilament lightsecondary progressive multiple sclerosis

Identifiers

PMID35946107
PMCPMC9493411
OpenAlexW4290989001

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.